Consano Bio Gains FDA Fast Track for C-1101
BURLINGTON, Mass., August 18, 2026 Consano Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
Biologic Therapy
Advertisement
Kyowa Kirin Wins EC Approval for Crysvita in Infants
GALASHIELS & MARLOW, United Kingdom, July 21, 2026 Kyowa Kirin EMEA has announced that the European Commission (EC) has...
Lilly’s EBGLYSS Wins FDA Approval for Reduced Injection Schedule
INDIANAPOLIS, United States, June 9, 2026 Eli Lilly and Company has secured U.S. Food and Drug Administration (FDA) approval...
Made Scientific Selected for Columbia’s NOVAKnee Program
PRINCETON, N.J., June 1, 2026 Made Scientific has been selected as the manufacturing partner for Columbia University’s NOVAKnee program,...
Yuka Report Highlights Ultra-Processed Food Crisis
NEW YORK, May 27, 2026 Yuka, the independent food and cosmetic scoring application used by more than 85 million...
Advertisements
Consano Bio Starts Phase 1 Trial for C-1101 Therapy
BURLINGTON, Massachusetts, May 26, 2026 Consano Bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for painful...
UCB Reports BIMZELX Superior to SKYRIZI in BE BOLD PsA Study
BRUSSELS, Belgium, May 19, 2026 UCB announced new Phase 3b clinical data showing that BIMZELX® (bimekizumab) demonstrated superior efficacy...
Keenova Highlights Updated XIAFLEX Data for Peyronie’s Disease at AUA 2026
DUBLIN, May 15, 2026 Keenova Therapeutics announced updated clinical findings on XIAFLEX® (collagenase clostridium histolyticum) for the treatment of...
AstraZeneca’s FASENRA Wins FDA Approval for HES
WILMINGTON, Del., May 14, 2026 AstraZeneca announced that the U.S. Food and Drug Administration has approved FASENRA® (benralizumab) for...
aTyr Pharma Advances Efzofitimod Phase 3 Sarcoidosis Program
SAN DIEGO, May 11, 2026 aTyr Pharma announced a major regulatory and clinical development update for its lead investigational...
Advertisement
